{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:40:04Z","timestamp":1744252804795,"version":"3.40.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04021-6","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:43:58Z","timestamp":1744217038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations between intercurrent events and cardiorenal clinical outcomes in non-diabetic chronic kidney disease: a\u00a0real-world retrospective cohort study in the United States"],"prefix":"10.1186","volume":"26","author":[{"given":"Christoph","family":"Wanner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schuchhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Frank\u00a0Kleinjung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsiana","family":"Vaitsiakhovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"4021_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","volume":"34","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34:1803\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"4021_CR2","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322:1294\u2013304.","journal-title":"JAMA"},{"key":"4021_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.semnephrol.2016.05.005","volume":"36","author":"RK Hsu","year":"2016","unstructured":"Hsu RK, Hsu CY. The role of acute kidney injury in chronic kidney disease. Semin Nephrol. 2016;36:283\u201392.","journal-title":"Semin Nephrol"},{"key":"4021_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339\u201352.","journal-title":"Lancet"},{"key":"4021_CR5","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238\u201352.","journal-title":"Lancet"},{"key":"4021_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709\u201333.","journal-title":"Lancet"},{"key":"4021_CR7","doi-asserted-by":"publisher","unstructured":"Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, et al. Design and baseline characteristics of the finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol Dialysis Transpl. 2024: https:\/\/doi.org\/10.1093\/ndt\/gfae132.","DOI":"10.1093\/ndt\/gfae132"},{"key":"4021_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2020.07.011","volume":"77","author":"AH Anderson","year":"2021","unstructured":"Anderson AH, Xie D, Wang X, Baudier RL, Orlandi P, Appel LJ, et al. Novel risk factors for progression of diabetic and nondiabetic CKD: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2021;77:56\u201373.","journal-title":"Am J Kidney Dis"},{"key":"4021_CR9","unstructured":"Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;2024(105):S117\u2013314."},{"key":"4021_CR10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"4021_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"4021_CR12","unstructured":"Bayer HealthCare Pharmaceuticals Inc. KERENDIA\u00ae (finerenone) Prescribing Information. 2022. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Kerendia_PI.pdf. Accessed 2 May 2024."},{"key":"4021_CR13","unstructured":"Bayer AG. KERENDIA\u00ae (finerenone) Summary of Product Characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kerendia. Accessed 14 Nov 2024."},{"key":"4021_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00467-015-3104-8","volume":"31","author":"EA Hartung","year":"2016","unstructured":"Hartung EA. Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol. 2016;31:381\u201391.","journal-title":"Pediatr Nephrol"},{"key":"4021_CR15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30:1735\u201345.","journal-title":"J Am Soc Nephrol"},{"key":"4021_CR16","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2215\/CJN.00600206","volume":"1","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol. 2006;1:874\u201384.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4021_CR17","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. E9(R1) statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials. 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical. Accessed 19 Apr 2024."},{"key":"4021_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1186\/s13063-021-05644-4","volume":"22","author":"BC Kahan","year":"2021","unstructured":"Kahan BC, Morris TP, White IR, Carpenter J, Cro S. Estimands in published protocols of randomised trials: urgent improvement needed. Trials. 2021;22:686.","journal-title":"Trials"},{"key":"4021_CR19","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Addendum on estimands and sensitivity analyses in clinical trials to the guideline on statistical principles for clinical trials, ICH E9 (R1). 2019. https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf. Accessed 23 Apr 2024."},{"key":"4021_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40620-022-01340-x","volume":"36","author":"C Wanner","year":"2023","unstructured":"Wanner C, Schuchhardt J, Bauer C, Lindemann S, Brinker M, Kong SX, et al. Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database. J Nephrol. 2023;36:45\u201354.","journal-title":"J Nephrol"},{"key":"4021_CR21","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1\u2013150."},{"key":"4021_CR22","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","volume":"323","author":"MJ Stensrud","year":"2020","unstructured":"Stensrud MJ, Hern\u00e1n MA. Why test for proportional hazards? JAMA. 2020;323:1401\u20132.","journal-title":"JAMA"},{"key":"4021_CR23","unstructured":"European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. Accessed 23 Apr 2024."},{"key":"4021_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/pst.2078","volume":"20","author":"Y Qu","year":"2021","unstructured":"Qu Y, Shurzinske L, Sethuraman S. Defining estimands using a mix of strategies to handle intercurrent events in clinical trials. Pharm Stat. 2021;20:314\u201323.","journal-title":"Pharm Stat"},{"key":"4021_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/picr.picr_384_20","volume":"12","author":"NJ Gogtay","year":"2021","unstructured":"Gogtay NJ, Ranganathan P, Aggarwal R. Understanding estimands. Perspect Clin Res. 2021;12:106\u201312.","journal-title":"Perspect Clin Res"},{"key":"4021_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17\u201328.","journal-title":"Kidney Int"},{"key":"4021_CR27","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.14074","volume":"22","author":"KI Birkeland","year":"2020","unstructured":"Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020;22:1607\u201318.","journal-title":"Diabetes Obes Metab"},{"key":"4021_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.ajkd.2017.04.018","volume":"70","author":"DM Charytan","year":"2017","unstructured":"Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, et al. ESRD after heart failure, myocardial infarction, or stroke in type 2 diabetic patients with CKD. Am J Kidney Dis. 2017;70:522\u201331.","journal-title":"Am J Kidney Dis"},{"key":"4021_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821\u201335.","journal-title":"Am J Kidney Dis"},{"key":"4021_CR30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1053\/j.ajkd.2019.12.005","volume":"75","author":"CP Walther","year":"2020","unstructured":"Walther CP, Nambi V, Hanania NA, Navaneethan SD. Diagnosis and management of pulmonary hypertension in patients with CKD. Am J Kidney Dis. 2020;75:935\u201345.","journal-title":"Am J Kidney Dis"},{"key":"4021_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/j.ajkd.2017.11.018","volume":"72","author":"M Tang","year":"2018","unstructured":"Tang M, Batty JA, Lin C, Fan X, Chan KE, Kalim S. Pulmonary hypertension, mortality, and cardiovascular disease in CKD and ESRD patients: a systematic review and meta-analysis. Am J Kidney Dis. 2018;72:75\u201383.","journal-title":"Am J Kidney Dis"},{"key":"4021_CR32","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"4021_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10557-016-6697-7","volume":"30","author":"P Pellicori","year":"2016","unstructured":"Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, et al. Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther. 2016;30:599\u2013609.","journal-title":"Cardiovasc Drugs Ther"},{"key":"4021_CR34","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"ME Grams","year":"2023","unstructured":"Grams ME, Coresh J, Matsushita K, Ballew SH, Sang Y, Surapaneni A, et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA. 2023;330:1266\u201377.","journal-title":"JAMA"},{"key":"4021_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","volume":"97","author":"CM Clase","year":"2020","unstructured":"Clase CM, Carrero JJ, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97:42\u201361.","journal-title":"Kidney Int"},{"key":"4021_CR36","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000437151","volume":"41","author":"GN Nakhoul","year":"2015","unstructured":"Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr, et al. Serum potassium, end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol. 2015;41:456\u201363.","journal-title":"Am J Nephrol"},{"key":"4021_CR37","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","volume":"39","author":"CP Kovesdy","year":"2018","unstructured":"Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39:1535\u201342.","journal-title":"Eur Heart J"},{"key":"4021_CR38","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"4021_CR39","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892\u2013903.","journal-title":"N Engl J Med"},{"key":"4021_CR40","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.3390\/ijerph17103495","volume":"17","author":"SY Chien","year":"2020","unstructured":"Chien SY, Chuang MC, Chen IP. Why people do not attend health screenings: factors that influence willingness to participate in health screenings for chronic diseases. Int J Environ Res Public Health. 2020;17:3495.","journal-title":"Int J Environ Res Public Health"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04021-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:05:02Z","timestamp":1744250702000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04021-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4021"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04021-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data used in this study were obtained from Optum\u00ae under a license to Bayer AG and are not publicly available. Data included in the Optum CDM database are de-identified and are in compliance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996 to preserve participant anonymity and confidentiality, and as such this study followed the principles of the declaration of Helsinki without the requirement for review from a formal ethics review committee. The use of the provided Optum\u00ae data was determined by the New England Institutional Review Board (IRB) to not constitute research involving human subjects and was therefore exempt from board oversight.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CW reports advisory board and lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, MSD, and Novo Nordisk. JS and CB are employees of MicroDiscovery GmbH, Berlin, Germany. MB is an employee of Bayer AG, Wuppertal, Germany. FK is an employee of Bayer AG, Berlin, Germany. TV was an employee of Bayer AG, Berlin, Germany at the time the study was performed and owns shares in Bayer AG. TV is now an employee of Boehringer Ingelheim Pharma GmbH & Co KG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}